Affimed NV Corporate Call Transcript
Good day, everyone, and welcome to Affimed's conference call. (Operator Instructions) As a reminder, today's conference call is being recorded.
I would now like to introduce your host for today's conference call, Alex Fudukidis, Head of Investor Relations at Affimed. Please go ahead.
Thank you, John. I'd like to welcome everyone, and thank you for joining us today to discuss clinical data presented by MD Anderson at AACR on the combination therapy of AFM13, pre-complexed cord blood-derived natural killer cells with AFM13, followed by 3 weekly infusions of AFM13 monotherapy.
I would also like to apologize for the late start to the call. We were experiencing technical difficulties.
On the call today, we have our CEO, Dr. Adi Hoess, and a special guest for today is Dr. Katy Rezvani, Professor of Stem Cell Transplantation and Cellular Therapy at the University of Texas MD Anderson Cancer Center. In addition to Adi and Dr. Rezvani, we have the rest of our management team: Dr. Andreas
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |